Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
IPO Year: 2021
Exchange: NASDAQ
Website: sophiagenetics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/18/2024 | $11.00 | Buy | Craig Hallum |
| 8/7/2024 | $10.00 → $5.00 | Overweight → Equal-Weight | Morgan Stanley |
| 6/27/2024 | $6.00 | Buy | Guggenheim |
| 11/29/2023 | $8.00 | Outperform | RBC Capital Mkts |
| 7/5/2023 | $10.00 | Overweight | JP Morgan |
| 1/3/2023 | $6.00 | Buy | BTIG Research |
| 11/23/2022 | $2.00 | Neutral | Credit Suisse |
| 2/15/2022 | $23.00 → $18.00 | Overweight | Morgan Stanley |
| 10/15/2021 | Outperform | Cowen | |
| 8/17/2021 | $24.00 | Overweight | Morgan Stanley |
Fastest customizable press release news feed in the world
LONDON, May 13, 2026 /CNW/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading pathology providers, to bring liquid biopsy testing to lung and breast cancer patients across the U.K. as part of NHS England's 'revolutionary blood test-first' program. Synnovis, a major provider for England's South East Genomic Medicine Service, worked with SOPHiA GENETICS to launch the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™. This innovative test, originally developed by Memorial Slo
BOSTON and ROLLE, Switzerland, May 5, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial ResultsRevenue was $21.7 million, up 22% year-over-yearGross margin was 68.0% on a reported basis and 75.4% on an adjusted basis, compared to 68.7% reported and 75.7% adjusted in the prior year periodIFRS net loss was $19.3 million, an increase of 11% year-over-year; Adjusted EBITDA loss was $9.2 million, improving 3% year-over-year"We st
BOSTON and ROLLE, Switzerland, April 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the first quarter 2026 before U.S. markets open on Tuesday, May 5, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be available on the websi
SAN DIEGO and NEW YORK, April 16, 2026 /CNW/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of the leading academic health systems in the United States, will adopt the AI-powered SOPHiA DDM™ Platform to advance cancer research and enhance genomic testing capabilities. Mount Sinai, a National Cancer Institute-designated Comprehensive Cancer Center in New York City, supports care for more than 4,000 oncology patients annually. Mount Sinai's Molecular Pathology team will leverage SOPHiA DDM™
BOSTON and ROLLE, Switzerland, March 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial ResultsRevenue was $21.7 million, up 22% year-over-yearGross margin was 67.7% on a reported basis and 73.9% on an adjusted basis, compared to 68.2% reported and 74.2% adjusted in the prior year periodIFRS net loss was $19.2 million, an increase of 27% year-over-year; Adjusted EBITDA loss was $9.9 million, an increas
BOSTON and ROLLE, Switzerland, Feb. 25, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced that leadership will present at TD Cowen's 46th Annual Health Care Conference in Boston. Jurgi Camblong, Chief Executive Officer and co-founder of SOPHiA GENETICS, and Ross Muken, President of SOPHiA GENETICS, will participate in a fireside chat on Wednesday, March 4, 2026, at 10:30 am EST / 4:30 pm CET. A live audio webcast of the fireside chat will be available here. Additionally, a replay of the webcast will be available
BOSTON and ROLLE, Switzerland, Feb. 17, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the fourth quarter and full year 2025 before U.S. markets open on Tuesday, March 3, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be availa
BOSTON and ROLLE, Switzerland, Feb. 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network. The two new institutions, which collectively analyze millions of genetic samples annually, include one of the leading nonprofit, multi-region integrated healthcare systems in the U.S. and a top 10 U.S. health system laboratory. Together, these institutions will leverage the AI-native, cloud-based SOPHiA DDM™ to analyze complex genomic data at scale.
The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to CEO BOSTON and ROLLE, Switzerland, Jan. 12, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today provided preliminary unaudited financial results for the fourth quarter and full year 2025, initiated its financial outlook for 2026, and announced an executive transition plan, including the promotion of Ross Muken to Chief Executive Officer (CEO), effective July 1, 2026, and the transition of co-Founder Jurgi Camblong to Executive Chairman.
BOSTON and HOUSTON, Jan. 7, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice. As part of the collaboration, MD Anderson and SOPHiA GENETICS are launching a series of research and de
6-K - SOPHiA GENETICS SA (0001840706) (Filer)
6-K - SOPHiA GENETICS SA (0001840706) (Filer)
6-K - SOPHiA GENETICS SA (0001840706) (Filer)
144 - SOPHiA GENETICS SA (0001840706) (Subject)
144 - SOPHiA GENETICS SA (0001840706) (Subject)
144 - SOPHiA GENETICS SA (0001840706) (Subject)
144 - SOPHiA GENETICS SA (0001840706) (Subject)
144 - SOPHiA GENETICS SA (0001840706) (Subject)
144 - SOPHiA GENETICS SA (0001840706) (Subject)
EFFECT - SOPHiA GENETICS SA (0001840706) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Craig Hallum initiated coverage of SOPHiA GENETICS SA with a rating of Buy and set a new price target of $11.00
Morgan Stanley downgraded SOPHiA GENETICS SA from Overweight to Equal-Weight and set a new price target of $5.00 from $10.00 previously
Guggenheim initiated coverage of SOPHiA GENETICS SA with a rating of Buy and set a new price target of $6.00
RBC Capital Mkts initiated coverage of SOPHiA GENETICS SA with a rating of Outperform and set a new price target of $8.00
JP Morgan resumed coverage of SOPHiA GENETICS SA with a rating of Overweight and set a new price target of $10.00
BTIG Research initiated coverage of SOPHiA GENETICS SA with a rating of Buy and set a new price target of $6.00
Credit Suisse initiated coverage of SOPHiA GENETICS SA with a rating of Neutral and set a new price target of $2.00
Morgan Stanley reiterated coverage of Sophia Genetics with a rating of Overweight and set a new price target of $18.00 from $23.00 previously
Cowen resumed coverage of SOPHiA GENETICS SA with a rating of Outperform
Morgan Stanley initiated coverage of Sophia Genetics with a rating of Overweight and set a new price target of $24.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
Live Leadership Updates
BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO. In the newly created role of company President, Ross Muken will oversee SOPHiA GENETICS's global business operations and work even more closely on strategic planning with CEO, Jurgi C
New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland, May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced SOPHiA UNITY, a new data-driven consortium designed to accelerate cancer research globally. SOPHiA UNITY aims to bring together leading healthcare institutions to progress a shared goal of furthering cancer research, advancing drug development and supporting data-driven patient care.
Microsoft's Deputy Chief Technology Officer to be appointed at Annual Shareholders' Meeting BOSTON and LAUSANNE, Switzerland, May 31, 2023 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the nomination of Lila Tretikov to its Board of Directors. The Board of Directors has proposed the appointment of Tretikov as a member of the board at the Annual General Meeting of Shareholders of SOPHiA GENETICS SA on June 26, 2023. An award-winning powerhouse in the global technology
BOSTON and LAUSANNE, Switzerland , May 5, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Cosséry to its Board of Directors. The Board of Directors will propose the appointment of Mr. Cosséry as a member of the Board of Directors and a member of the Compensation Committee to the Annual General Meeting of Shareholders of SOPHiA GENETICS SA, to convene on June 15, 2022. "A thoughtful and passionate leader, Jean-Michel offers a tremendous diversity of experiences across functions, companies, and
BOSTON and LAUSANNE, Switzerland, Jan. 26, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (NASDAQ:SOPH), the creator of a global data pooling and knowledge sharing platform that democratizes data-driven medicine, today announced that Ken Freedman has been appointed Chief Revenue Officer. With a background in serving some of the most innovative providers of technology to the world-wide media space, Ken brings more than 25 years of sales, marketing, and executive management experience. Previously, Ken was the Executive Vice President of Sales for Naviga where he grew revenue streams, b
This live feed shows all institutional transactions in real time.
SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)
SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)
SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)
SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)
SC 13D/A - SOPHiA GENETICS SA (0001840706) (Subject)
SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)
SC 13D - SOPHiA GENETICS SA (0001840706) (Subject)
SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)
SC 13G - SOPHiA GENETICS SA (0001840706) (Subject)
SC 13G - SOPHiA GENETICS SA (0001840706) (Subject)
Live finance-specific insights
BOSTON and ROLLE, Switzerland, May 5, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial ResultsRevenue was $21.7 million, up 22% year-over-yearGross margin was 68.0% on a reported basis and 75.4% on an adjusted basis, compared to 68.7% reported and 75.7% adjusted in the prior year periodIFRS net loss was $19.3 million, an increase of 11% year-over-year; Adjusted EBITDA loss was $9.2 million, improving 3% year-over-year"We st
BOSTON and ROLLE, Switzerland, April 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the first quarter 2026 before U.S. markets open on Tuesday, May 5, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be available on the websi
BOSTON and ROLLE, Switzerland, March 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial ResultsRevenue was $21.7 million, up 22% year-over-yearGross margin was 67.7% on a reported basis and 73.9% on an adjusted basis, compared to 68.2% reported and 74.2% adjusted in the prior year periodIFRS net loss was $19.2 million, an increase of 27% year-over-year; Adjusted EBITDA loss was $9.9 million, an increas
BOSTON and ROLLE, Switzerland, Feb. 17, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the fourth quarter and full year 2025 before U.S. markets open on Tuesday, March 3, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be availa
BOSTON and ROLLE, Switzerland, Nov. 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Revenue was $19.5 million, up 23% year-over-yearGross margin was 66.3% on a reported basis and 73.1% on an adjusted basis, compared to 67.2% reported and 73.1% adjusted in the prior year periodNet IFRS loss was $20.0 million, up 9% year-over-year; Adjusted EBITDA loss was $10.2 million, up 8% year-over-year; Excluding the i
Highlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations.Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively. Third quarter 2025 gross margin was 69.9%. Third quarter 2025 GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00. Third quarter 2025 adjusted EBITDA was $10.3 million.Entered a strategic collaboration with SOPHiA GENETICS (NASDAQ:SOPH) to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) te
BOSTON and ROLLE, Switzerland, Oct. 21, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the third quarter 2025 before U.S. markets open on Tuesday, November 4, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be available on the
BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Revenue was $18.3 million, up 16% year-over-yearGross margin was 67.0% on a reported basis and 74.4% on an adjusted basis, up from 68.2% reported and 73.2% adjusted in the prior year periodIFRS net loss increased 48% year-over-year to $22.4 million (or 23% excluding foreign exchange impact); Adjusted EBITDA
BOSTON and ROLLE, Switzerland, July 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the second quarter 2025 before U.S. markets open on Tuesday, August 5, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will
BOSTON and ROLLE, Switzerland, May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basisGross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectivelyIFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign excha